Outcomes of malignant orbital tumors: a 22-year Norwegian single-center series
By
Bendik Alvheim Sundfjord
Julie Selvik Bentzon
Signe Johnsen Landa
Svein Arthur Jensen
Dorota Goplen
Jon Espen Dale
Stein Lybak
Hans Olav Ueland
Eyvind Rødahl
June 24, 2026
Clinical Scorecard: Long-term Results of Malignant Orbital Tumors: A 22-Year Study from a Norwegian Single-Center Experience
At a Glance
Category Detail
Condition Malignant Orbital Tumors Key Mechanisms Tumors can be primary or secondary, with various histological subtypes. Target Population Patients with malignant orbital tumors treated at Haukeland University Hospital. Care Setting Ophthalmology department at a referral center in Western Norway.
Key Highlights
76 patients included, with a median age of 64 years at diagnosis. Most common tumor types: secondary invading tumors (46%), lymphoproliferative (24%), metastatic (16%), primary orbital tumors (14%). Overall disease-specific 5-year survival rate was 59%, varying by tumor type. Surgical removal was performed in 55% of patients, with 72% receiving local radiotherapy. Incidence of malignant orbital tumors in Western Norway estimated at 0.30 per 100,000 inhabitants. Guideline-Based Recommendations
Diagnosis
Biopsy and histopathologic confirmation are essential for diagnosis. Management
Treatment options include surgery, radiotherapy, and chemotherapy based on histological features and staging. Monitoring & Follow-up
Regular follow-up for local/regional relapses or distant metastases is recommended. Risks
Higher risk of local/regional relapses or distant metastases observed in 42% of patients. Patient & Prescribing Data
Patients with malignant orbital tumors treated from 1999 to 2020.
Multimodal treatments have improved outcomes, with a focus on less invasive techniques.
Clinical Best Practices
Prompt diagnosis and treatment are crucial for better prognosis. Consideration of volume-outcome relationships in treatment settings. Related Resources & Content
